SLDB: Advancing gene therapies for DMD and FA with novel delivery platforms and global ambitions
Gene therapy programs for DMD and FA are advancing, with high demand and robust biomarker strategies supporting clinical development. Novel capsid technology enables superior biodistribution and safety, while streamlined FA procedures and global expansion plans position the company for significant…
Story updates
09:23:04 PM UTC
SquawkNews
The company is advancing gene therapies for DMD and FA, with high demand and robust clinical progress. Novel delivery platforms and optimized constructs drive strong safety and efficacy signals, with pivotal data and regulatory updates expected by early next year.Based on Solid Biosciences Inc. [SL…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.